Marie M Onakomaiya1, Leslie P Henderson2. 1. Cherokee Nation Technology Solutions Contractor to: The National Intrepid Center of Excellence (NICoE) Network Research Program, Walter Reed National Military Medical Center, 4860 South Palmer Road, Bethesda, MD, 20889, USA. marie.m.onakomaiya.gr@dartmouth.edu. 2. Department of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth, HB 7701, Hanover, NH, 03755, USA.
Abstract
RATIONALE: For several decades, elite athletes and a growing number of recreational consumers have used anabolic androgenic steroids (AAS) as performance enhancing drugs. Despite mounting evidence that illicit use of these synthetic steroids has detrimental effects on affective states, information available on sex-specific actions of these drugs is lacking. OBJECTIVES: The focus of this review is to assess information to date on the importance of sex and its interaction with other environmental factors on affective behaviors, with an emphasis on data derived from non-human studies. METHODS: The PubMed database was searched for relevant studies in both sexes. RESULTS: Studies examining AAS use in females are limited, reflecting the lower prevalence of use in this sex. Data, however, indicate significant sex-specific differences in AAS effects on anxiety-like and aggressive behaviors, interactions with other drugs of abuse, and the interplay of AAS with other environmental factors such as diet and exercise. CONCLUSIONS: Current methods for assessing AAS use have limitations that suggest biases of both under- and over-reporting, which may be amplified for females who are poorly represented in self-report studies of human subjects and are rarely used in animal studies. Data from animal literature suggest that there are significant sex-specific differences in the impact of AAS on aggression, anxiety, and concomitant use of other abused substances. These results have relevance for human females who take these drugs as performance-enhancing substances and for transgender XX individuals who may illicitly self-administer AAS as they transition to a male gender identity.
RATIONALE: For several decades, elite athletes and a growing number of recreational consumers have used anabolic androgenic steroids (AAS) as performance enhancing drugs. Despite mounting evidence that illicit use of these synthetic steroids has detrimental effects on affective states, information available on sex-specific actions of these drugs is lacking. OBJECTIVES: The focus of this review is to assess information to date on the importance of sex and its interaction with other environmental factors on affective behaviors, with an emphasis on data derived from non-human studies. METHODS: The PubMed database was searched for relevant studies in both sexes. RESULTS: Studies examining AAS use in females are limited, reflecting the lower prevalence of use in this sex. Data, however, indicate significant sex-specific differences in AAS effects on anxiety-like and aggressive behaviors, interactions with other drugs of abuse, and the interplay of AAS with other environmental factors such as diet and exercise. CONCLUSIONS: Current methods for assessing AAS use have limitations that suggest biases of both under- and over-reporting, which may be amplified for females who are poorly represented in self-report studies of human subjects and are rarely used in animal studies. Data from animal literature suggest that there are significant sex-specific differences in the impact of AAS on aggression, anxiety, and concomitant use of other abused substances. These results have relevance for human females who take these drugs as performance-enhancing substances and for transgender XX individuals who may illicitly self-administer AAS as they transition to a male gender identity.
Authors: Sean Esteban McCabe; Kirk J Brower; Brady T West; Toben F Nelson; Henry Wechsler Journal: Drug Alcohol Depend Date: 2007-05-23 Impact factor: 4.492
Authors: Marisa Roberto; Maureen T Cruz; Nicholas W Gilpin; Valentina Sabino; Paul Schweitzer; Michal Bajo; Pietro Cottone; Samuel G Madamba; David G Stouffer; Eric P Zorrilla; George F Koob; George R Siggins; Loren H Parsons Journal: Biol Psychiatry Date: 2010-01-08 Impact factor: 13.382
Authors: Isabel M Quadros; Lara S Hwa; Akiko Shimamoto; Julia Carlson; Joseph F DeBold; Klaus A Miczek Journal: Neuropsychopharmacology Date: 2014-06-11 Impact factor: 7.853
Authors: Giuseppe Bertozzi; Francesco Sessa; Giuseppe Davide Albano; Gabriele Sani; Francesca Maglietta; Mohsin H K Roshan; Giovanni Li Volti; Renato Bernardini; Roberto Avola; Cristoforo Pomara; Monica Salerno Journal: Mol Neurobiol Date: 2017-10-02 Impact factor: 5.590
Authors: William Byne; Dan H Karasic; Eli Coleman; A Evan Eyler; Jeremy D Kidd; Heino F L Meyer-Bahlburg; Richard R Pleak; Jack Pula Journal: Transgend Health Date: 2018-05-01